Eli Lilly to Invest £279 Million ($364 Million) in UK Biotech and Weight-Loss Jabs Trial

Oct 15, 2024, 07:56 AM

Eli Lilly plans to invest £279 million ($364 million) in the UK to support biotechs and conduct research on the impact of its drugs for diabetes and obesity on healthcare resources. This investment is part of a broader initiative that includes a government-backed trial to provide weight-loss jabs to unemployed individuals with obesity. Health Secretary Wes Streeting announced the trial, which aims to help the unemployed return to work and reduce NHS costs. Prime Minister Keir Starmer has endorsed the initiative. The initiative has sparked debate on its potential economic benefits and ethical implications.